Over the last 40 years, Besins Healthcare has discovered, developed and delivered healthcare solutions to help women successfully manage the often unexpected issues related to pregnancy to preterm birth and menopause. Our estrogen-based and progesterone-based products are confidently prescribed by physicians in more than 100 countries worldwide.
We are a major player in Menopause Hormone Therapy (MHT), being the first company to develop a transdermal estradiol gel in the seventies and the first to develop a micronised natural progesterone formulation bioavailable by oral and vaginal routes of administration.
Luteal phase support, threatened and recurrent miscarriage, pre-term birth, vulvovaginal atrophy, irregular bleeding, cycle control, hormone replacement therapy in menopause and mastodynia are core areas of focus for Besins. We remain committed to discovering innovations in gynaecology, fertility and obstetrics.
Infertility is defined as the inability of a sexually active couple who are not using birth control to become pregnant after one year of trying. An estimated 35 to 40 percent of infertility cases are due to female infertility and an equal number can be due to male infertility. Approximately 20% of infertility cases occur from an unknown cause.
Luteal phase deficiency (LPD) has been associated with infertility. It is described as a condition in which endogenous progesterone is not sufficient to maintain functional secretory endometrium and allow normal embryo implantation and growth .
Exogenous progesterone (also named Luteal Phase Support or LPS) is a common element in the treatment regimen in infertility, particularly those related to Assisted Reproductive Technologies (ART).
A preterm birth is defined as a live baby born before 37 weeks of pregnancy are completed. An estimated 15 million babies are born preterm every year and this number is rising. Over 1 million babies die annually from preterm birth complications and it is the leading cause of newborn deaths (babies in the first four weeks of life) and the second leading cause of death after pneumonia in children under five years .
Menopause is a stage in life when a woman stops having her monthly period and is diagnosed when she has gone without a period for 12 consecutive months in the absence of other pathological or physiological causes. It is a normal part of ageing and marks the end of a woman’s reproductive years. Menopause typically occurs in a woman’s late 40s to early 50s. However, women who have their ovaries surgically removed undergo “sudden” menopause. Approximately 75 % of women experience hot flushes and night sweats at some point during perimenopause and most women will have symptoms for 5 to 10 years .
The impact of hot flushes on quality of life may be considerable and is often underestimated. Hot flushes and night sweat negatively affect the quality of life for an estimated 20 – 25 % of women, due to physical discomfort and social embarrassment, with night sweats associated with sleep disruption .